The Company's focus is on the development of anti-inflammatory treatments for rare diseases with significant unmet needs. Proteo is engaged in the development of pharmaceuticals based on the body's own tools and weapons to fight inflammatory diseases.

News

2013-03-20

FDA grants Orphan Drug Designation to Elafin for prevention of inflammatory complications of transthoracic esophagectomy

2013-01-10

FDA grants Proteo Orphan Drug Designation to Elafin for the treatment of pulmonary arterial hypertension

2012-12-11

Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)

See full list




PROTEO BIOTECH AG
Am Kiel-Kanal 44
24106 Kiel
Germany
phone: +49 431 8888462
http://proteo.de/pages/ – printed on 2013-06-18 23:18:29